1

Building Canada’s leading specialty pharmaceutical company

Knight Therapeutics Inc.(TSX: GUD)

June 2017

This document contains forward-looking statements for the Company and its subsidiaries.

These forward looking statements, by their nature, necessarily involve risks and uncertainties

that could cause actual results to differ materially from those contemplated by the forward-

looking statements. The Company considers the assumptions on which these forward-looking

statements are based to be reasonable at the time they were prepared, but cautions the

reader that these assumptions regarding future events, many of which are beyond the control

of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks,

which could cause actual results to differ materially from current expectations are discussed in

the Company’s Annual Report and in the Company’s Annual Information Form for the year

ended December 31, 2016. The Company disclaims any intention or obligation to update or

revise any forward-looking statements whether as a result of new information or future

events, except as required by law.

2

Forward Looking Statements

• Better a Gud Knight than a bad one

• We never rest at Knight

• May you always have a Gud-Knight

• A Gud-Knight is Gud Medison

• Knighting wrong with making money

• Gud for Knight

• Fun things happen at Knight

• Knight loves a Gud pun

• Gud Knight sleep tight

• Gud time had by all

• Gudluck Jonathan

3

A Knight is Born

4

A Knight’s History

• Founded by co-founder & CEO of Paladin Labs Inc.– 19 years of consecutive record revenues

– Share price increased from $1.50 to $151 per share

– Market capitalization increased from $6 million to $3.2 billion

• Knight’s first day was on February 28th, 2014– The day Paladin’s sale to Endo closed

– Knight initially owned by Paladin’s shareholders as consideration for Paladin sale

Knight is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products

for the Canadian and select international markets

Since starting operations in 2014 with 2 employees, $1M in cash, a single therapeutic pending FDA approval, Knight:

5

Learning to Walk

1 As at March 31, 2017, includes approximately $9M of foreign exchange gains

• Raised $685M at increasing valuations ($3.50, $5.25, $6.75, $8.00, $10.00 per share)

• Received FDA approval for Impavido® in March 2014 and sold PRV for US$125M

• In-licensed over 20 innovative pipeline products from 14 companies

• Acquired NeurAxon Inc., Orphan Canada assets and Neuragen brand

• Sold or out-licensed rights to Neuragen, Impavido and NeurAxon

• Expanded internationally through strategic partnership with Medison (Israel)

• Lent over $125M to 12 strategic loan partners and generated 15+% return

• Committed ~$125M to nine fund managers as part of long-term licensing strategy

• Generated ~$185M1 of net income to date

Significant Achievements Since Founding

6

Growth Strategies

In-licensing or Acquiring Product Rights

Strategic Fund Investments

Strategic Lending For Product Rights

Near Term Pipeline Long Term Pipeline Near and Long Term Pipeline

• In-license innovative pharmaceuticals

• Acquire mature or under-promoted products from Big Pharma

• Develop near-term, low risk/low expense products for the Canadian and global markets

• Committed ~$125M to various funds

• Nine fund investments closed to date

• Two licensing deals closed

• Secured against revenue and/or tangible assets

• IP not taken as only security

• Structured with returns between 15%-20% including interest, warrants, equity and product rights

Firing on Multiple Cylinders

Building a portfolio of innovative pharmaceuticals

Product Portfolio

7

Expanding Pipeline of Innovative Pharmaceuticals

8

Product Selection Criteria

DiscoveryPre Clinical

ModelsClinical Trials

Regulatory Approval

Sales and Marketing

• Focus on later stage products (Phase II, Phase III or approved in foreign market)

• Structure transaction to meet partner needs while protecting downside risk

• Manage return to address associated risks

Knight’s involvement

2 - 10 Years 2 - 4 Years 5 - 7 Years 1 - 3 Years

Taking on Commercialization Risk, NOT Development Risk

9

Movantik®

Background

• Exclusive license agreement with AstraZeneca for Movantik® in Canada and Israel

• First oral once-daily peripherally acting mu-opioid receptor antagonist (PAMORA) to be approved in Canada (launched in Canada in October 2015)

Opportunity

• Opioid induced constipation (OIC) affects between 26%-79% of patients taking an oral opioid1,2

• Strengthens Knight’s opioid supportive care portfolio along with Probuphine

• Knight began commercial launch in March 2017 – calling on over 3,000 physicians - 11% of prescribers who represents >50% of Rx

1. Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-cancer Pain2. Chronic opioid induced constipation in patients with non-malignant pain

Treatment of opioid-induced constipation

Background

• Exclusive in-license agreement with Braeburn for Canada

• Subdermal implant for opioid addiction

• Delivers buprenorphine continuously for six months

• Expected to be submitted for Canadian regulatory approval in Q2-2017

Opportunity

• Small number of prescribers that overlap opioid support portfolio

• Addresses issue of patient adherence/compliance

• Addresses issue of diversion/illicit use

10

Probuphine™Novel implant for opioid addiction

Iluvien®(Implant for diabetic macular edema)

• Exclusive in-license agreement with Alimera Sciences

• Continuous micro-dosing over 3 years for the treatment for vision impairment associated with DME

• Approximately 200 retinal specialists in Canada

• New Drug Submission accepted for review by Health Canada in February 2017

11

Ophthalmology Portfolio Differentiated Therapies for targeted physicians

Netildex™(Combination antibiotic/steroid for eye infection/inflammation)

• Exclusive in-license agreement with SIFI for Netildex™ in Canada

• Introduces a new antibiotic with a known steroid leading to less resistance

• Good fit within growing ophthalmic portfolio

• Submission for regulatory approval with Health Canada expected during the second half of 2017

12

Impavido®

Background

• Acquired global rights from Paladin Labs at founding of Knight

• Approved and licensed in Germany and Israel• Obtained US approval in March 2014 along with a

Priority Review Voucher• Sold Priority Voucher to Gilead for US$125M

Opportunity

• Launched in US through Profounda, Knight’s license partner, in Q1-2016

• Pursuing licensing opportunities for Impavido® in Latin America

• Pursuing acquisition and in-licensing opportunities for other tropical disease products

Treatment for Leishmaniasis (visceral, mucosal and cutaneous)

13

Prescription Pharmaceuticals

Product / Family Licensor Indication Status in Territory Territory Rights1

Pain

Movantik® AstraZeneca Opioid-induced constipation Marketed3 CAN, ISR

Probuphine™ Braeburn Opioid addiction Pre-Registration CAN

NeurAxon family N/A Acute migraine, pain and neurological disorders Pre-Clinical – Phase 3 CAN, ISR, RUS, ZAF

Antibe family Antibe Chronic pain and inflammation Pre-clinical – Phase 2 CAN, ISR, RUS, ZAF

Ophthalmic

AzaSite™ Akorn Bacterial conjunctivitis Approved CAN

Iluvien® Alimera Diabetic macular edema NDS in Review CAN

Netildex™ SIFI Ocular inflammation Pre-Registration CAN

Other

Impavido® N/A Leishmaniasis Marketed Global2

ATryn® LFB Prevention of thromboembolic events Pre-Registration4 CAN

60P family 60P Tropical diseases Phase 1 – Phase 3 CAN, ISR, RUS

Advaxis family Advaxis HPV-associated cancers and others Phase 1 – Phase 2 CAN

1 Legend: CAN: Canada, ISR: Israel, ROM: Romania, RUS: Russia, ZAF: Sub-Saharan Africa2 Approved in Germany, Israel and the U.S. (Distributed by Profounda in the U.S.)3 Currently approved and marketed in Canada only4 Knight received a Notice of Deficiency Withdrawal from Health Canada in March 2017

14

Consumer Health Products

Product / Family Licensor Description Status in Territory Territory Rights1

Neuragen® OwnedPain associated with diabetic and peripheral neuropathy

Marketed2 Global (Ex. U.S.)

Flat Tummy Tea™ Synergy Herbal detox tea Marketed CAN, ISR, ROM, RUS, ZAF

FOCUSfactor™ Synergy Dietary supplement Marketed3 CAN, ISR, ROM, RUS, ZAF

FLEXISEQ™ Pro Bono BioPain and joint stiffness associated with osteoarthritis

Not Yet Marketed QUE, ISR

Hand MD™ Synergy Line of anti-aging hand skincare products Not Yet Marketed CAN, ISR, ROM, RUS, ZAF

Crescita family Crescita Dermo-cosmetic products lines Not Yet Marketed CAR, ISR, ROM, RUS, ZAF

1 Legend: CAN: Canada, CAR: the Caribbean, ISR: Israel, QUE: Quebec, ROM: Romania, RUS: Russia, ZAF: Sub-Saharan Africa2 Approved and marketed by Knight in Canada only3 Approved and marketed in Canada only

15

Medical Devices / Diagnostics

Product / Family Licensor Indication / Description Status in Territory Territory Rights1

TULSA-PRO® Profound Prostate ablation Pre-Registration CAN

3D Signatures family 3D SignaturesDiagnostic and prognostic tools to improve treatment outcomes

In Development CAN, CAR, ISR, ROM, RUS, ZAF

1 Legend: CAN: Canada, CAR: the Caribbean, ISR: Israel, ROM: Romania, RUS: Russia, ZAF: Sub-Saharan Africa

Strategic Fund Strategy

16

Long-term Path for Product Rights

• Strategy: Knight invests in life sciences venture capital funds in order to obtain preferential access to innovative pharmaceutical products and earn LP returns

• Investment: ~C$125M invested in nine funds in Canada, Europe and US with proven track record of positive returns

• Results: Fund strategy led to license of Iluvien® from Alimeraand license agreement with Advaxis for their portfolio of products for Canada

17

Fund Strategy OverviewDiversifying Access to Products

18

Strategic Fund Portfolio

Fund Amount Healthcare AUM Development Stage Geography

Teralys C$30M C$450M VCAP Fund of Funds Canada

Domain US$25M US$2.4B Early stage North America

Forbion €19.5M EUR€400M All clinical stages Europe

Sectoral US$13M US$3.6B Late stage to small cap Global

Sanderling US$10M US$900M Early stage North America

HarbourVest C$10M US$2.3B VCAP Fund of Funds Canada

TVM US$1.6M EUR€1.3B All clinical stages Global

Bloom Burton2 C$1.5M C$50M Commercial stage Canada

Genesys C$1M C$200M Early stage North America

Total1 ~C$125M All stages Worldwide

1 Total in CAD is converted at the Bank of Canada noon exchange rates as of the commitment dates. Using the March 31, 2017 exchange rates, total fund commitments are C$135M with C$99M remaining to be funded.

2 Bloom Burton healthcare lending trusts are managed by Stratigis Capital AdvisorsSource: Fund information provided by fund managers

Commitments to Date

19

A GUD Track RecordNotable Investments by Knight’s Partner Funds

Strategic LendingAnother Source of Products and Return on Investment

20

• Strategy: Enter into secured loans with life-sciences companies in exchange for product rights for Canada and select international markets

• Investment: Over C$125M loaned to 12 strategic loan partners generating 15+% annual return on invested capital

• Results: 15+ innovative products in Knight’s portfolio have been sourced via secured lending strategy

21

Strategic Lending OverviewLeveraging Knight’s Balance Sheet for Products

22

Strategic Lending Portfolio

CompanyPrincipal Loaned5

Interest Rate1 Maturity2

ProductRights

Medimetriks US$23.0M 13% 2019

Synergy US$11.5M 15% 2017

Crescita3 C$6.8M 9% 2022

Profound C$4.0M 15% 2019

60P Pharma US$4.1M 15% 2020

Pediapharm4 C$1.25M 12% 2019

Ember US$1.0M 12.5% 2016

Antibe C$0.5M 10% 2018

1 Interest rate may be reduced by up to 2% should certain fundraising targets be met2 Some loans may be extended provided certain sales and profitability milestones are met3 Crescita acquired INTEGA Skin Sciences Inc.4 Pediapharm debenture is held indirectly through the Bloom Burton Healthcare Lending Trust5 As at March 31, 2017, Knight has loans receivable of C$54M

23

Strategic Lending Benefits All

CRH Knight

• CRH stock price increased by more than 3x within 4 months following loan

• Raised C$27M of equity at $3.40 per share and prepaid ~25% of Knight loan

• Prepaid balance of Knight loan in and replaced it with bank debt at 3.5%

• Increased market cap from ~$30M pre-Knight to over $500M two years later

• Sold CRH shares received as part of loan for proceeds of ~C$9.9M

• Successfully exited CRH loan following early repayment

• Earned an all-in IRR of 40+% in less than 12 months

CRH Medical – US$30 Million Secured Loan

24

Security Provides Greater Value

• Following default, Knight acquired

global rights to Neuragen®

• Sold the US rights to Synergy CHC

for proceeds of US$1.2M within 4

days of acquiring global rights

• Knight markets Neuragen® in

Canada – generating over $250K of

annual sales

• Pursuing out-licensing

opportunities for Rest of World

Origin Biomed – C$850K Secured Loan

Rest of World Pharma

25

Finding Other Knights

26

Rest of World Strategy

Vision Target Geographies

• Rest of World (outside US, Europe, Japan) specialty pharma will continue to experience growth

• Knight will be partner of choice for 2nd / 3rd tier markets

• Leverage GUD financial strength and business development capabilities to accelerate growth in each of these markets

• Knight has licensed rights to 15+ products for select international markets

• High growth countries with expanding access and funding for medicines

• Stable legal and regulatory systems, including IP protection

• Non-core geographies for other companies

• Knight acquired 28.3% of Medison Biotech (1995) Ltd., an Israeli specialty pharma company

Small Markets – Single Partner

• In September 2015, Knight acquired 28.3% ($80 million) of Medison Biotech (1995) Ltd. in exchange for 10% of Knight1

• Founded in 1996, Medison has grown to sales of approximately $206M in 2016

• Medison represents 20+ European and American pharmaceutical and biotech companies including Amgen®, Biogen® and Ipsen®

• As at March 31, 2017, Knight had received dividends from Medison totalling $6.9M

27

GUD MedisonInvestment in Medison Biotech

1 Medison ownership of Knight is currently below 10% due to dilution

Why Knight?

28

Partner of Choice for Canada and RoW

29

Knight’s Management Experience

Partnering• Built Canadian business through collaborations with over 30 companies• Deals structured to meet partners’ needs

Regulatory• Significant experience in all aspects of the regulatory process• ~30 submissions to Health Canada with a 90% success rate

Pricing and Reimbursement

• Extensive experience and success with PMPRB, provincial formularies and private payors • PMPRB acceptance of all major brands’ launch prices• Track record in obtaining significant price increases in public markets• Successfully negotiated favourable listings

Commercial• Commercialized over 60 products • Grew Canadian revenue to ~$150M and international revenue to ~$120M• Built sales and marketing teams/expertise across multiple therapeutic areas

Building Bench Strength

30

Management Team

Jonathan Ross Goodman B.A., LL.B., M.B.A.

Chief Executive Officer

• Paladin Labs, Co-Founder, President & CEO

• Procter & Gamble, Brand Management

Samira Sakhia, CPA, M.B.A.

President

• Paladin Labs, Chief Financial Officer

Jeffrey Kadanoff, B. Eng., M.B.A.

Chief Financial Officer

• Reitmans, VP Strategic Planning and Development

• Bain & Company, Principal

Amal Khouri, B.Sc., M.B.A.

VP Business Development

• Novartis, Global Business Development and Licensing

• Paladin Labs, Business Development

31

Board of Directors

Board Member Qualifications

James Gale (Chairman)• Paladin Labs, Board member from 2008 to 2014• Signet Healthcare Partners, Managing Director

Dr. Sarit Assouline• Jewish General Hospital, Director of the Chronic

Myelogenous Leukemia Clinic

Jonathan Ross Goodman • Knight Therapeutics, Founder and CEO• Paladin Labs, Co-founder, President & CEO

Meir Jakobsohn • Medison Pharma, Founder and CEO

Robert Lande • Paladin Labs, Board member from 1995 to 2014• Forex Capital Markets, CFO

Samira Sakhia• Knight Therapeutics, President• Paladin Labs, CFO from 2001 to 2015

Sylvie Tendler• Pharmaceutical Market Research Consultant• The Tendler Group Inc., Founder

32

Financial and Strategic Assets

Asset Description

Cash $764 million1 ($5.35 / share)

Marketed ProductsMovantik®, Impavido®, Neuragen®, Flat Tummy Tea™, FOCUSFactor®

Products Pending Approval/Submission Iluvien®, Netildex™, Probuphine™

Product Pipeline 20+ products in various stages of development

Strategic Fund Investments ~$125 million2 in total commitments

Strategic Loans ~$54 million3 of loans receivable

Rest of World Pharma ~$80M equity investment in Medison (28.3%)

1 Cash, cash equivalents and marketable securities as at March 31, 20172 Based on the exchange rates in effect on the dates of the fund commitments3 As at March 31, 2017, based on the exchange rates in effect on that date

• Proven ability to develop a rich pipeline of new

products

• Proven ability to secure profitable licensing and

secured loan agreements

• Proven track record of profitable growth

• Experienced and dynamic management team

• Financial strength to execute our strategy

33

Summary

Building Canada’s leading specialty pharmaceutical company

34June 2017

Knight Therapeutics Inc.(TSX: GUD)